(9H-carbazol)-2-yloxyacetic acid | 300345-74-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (9H-carbazol)-2-yloxyacetic acid
• 英文别名: Acetic acid, (9H-carbazol-2-yloxy)-；2-(9H-carbazol-2-yloxy)acetic acid
• CAS: 300345-74-8
• 化学式: C₁₄H₁₁NO₃
• 分子量: 241.246
• InChiKey: DBTXBCCOKOKVMR-UHFFFAOYSA-N

物化性质

• 沸点：
  507.9±25.0 °C(Predicted)
• 密度：
  1.409±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  62.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (9H-carbazol)-2-yloxyacetic acid 在 二乙胺基三氟化硫 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 6.25h， 生成 4-{[4-(2-methoxyphenoxymethyl)-4,5-dihydro-1,3-oxazol-2-yl]methoxy}-9H-carbazole
  参考文献：
  名称：

  Novel Carvedilol Analogues That Suppress Store-Overload-Induced Ca²⁺ Release

  摘要：

  Carvedilol is a uniquely effective drug for the treatment of cardiac arrhythmias in patients with heart failure. This activity is in part because of its ability to inhibit store-overload-induced calcium release (SOICR) through the RyR2 channel. We describe the synthesis, characterization, and bioassay of ca. 100 compounds based on the carvedilol motif to identify features that correlate with and optimize SOICR inhibition. A single-cell bioassay was employed on the basis of the RyR2-R4496C mutant HEK-293 cell line in which calcium release from the endoplasmic reticulum through the defective channel was measured. IC50 values for SOICR inhibition were thus obtained. The compounds investigated contained modifications to the three principal subunits of carvedilol, including the carbazole and catechol moieties, as well as the linker chain containing the beta-amino alcohol functionality. The SAR results indicate that significant alterations are tolerated in each of the three subunits.

  DOI：

  10.1021/jm401090a
• 作为产物：
  描述：

  4-羟基咔唑 在 potassium hydroxide 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 (9H-carbazol)-2-yloxyacetic acid
  参考文献：
  名称：

  Novel Carvedilol Analogues That Suppress Store-Overload-Induced Ca²⁺ Release

  摘要：

  Carvedilol is a uniquely effective drug for the treatment of cardiac arrhythmias in patients with heart failure. This activity is in part because of its ability to inhibit store-overload-induced calcium release (SOICR) through the RyR2 channel. We describe the synthesis, characterization, and bioassay of ca. 100 compounds based on the carvedilol motif to identify features that correlate with and optimize SOICR inhibition. A single-cell bioassay was employed on the basis of the RyR2-R4496C mutant HEK-293 cell line in which calcium release from the endoplasmic reticulum through the defective channel was measured. IC50 values for SOICR inhibition were thus obtained. The compounds investigated contained modifications to the three principal subunits of carvedilol, including the carbazole and catechol moieties, as well as the linker chain containing the beta-amino alcohol functionality. The SAR results indicate that significant alterations are tolerated in each of the three subunits.

  DOI：

  10.1021/jm401090a

文献信息

• METHOD FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES THROUGH AZIDES
  申请人：Asahi Kasei Kabushiki Kaisha

  公开号：EP1174426A1

  公开（公告）日：2002-01-23

  The present invention is directed to processes for the preparation of a tricyclic amino-alcohol derivative useful for treating and preventing diabetes, obesity, hyperlipidemia and the like, which compound is represented by the formula (1): wherein R1 represents a lower alkyl group or a benzyl group; *1 represents an asymmetric carbon atom; R2 represents a hydrogen atom, a halogen atom or a hydroxyl group; and A represents one of the following groups: wherein X represents NH, O or S; R5 represents a hydrogen atom, a hydroxyl group, an amino group or an acetylamino group; and *2 represents an asymmetric carbon atom when R5 is not a hydrogen atom. The processes of the present invention proceed via azide derivatives and are convenient, practical preparing processes with low cost which comprise a small number of steps with good industrial work efficiency.

  本发明涉及一种用于治疗和预防糖尿病、肥胖、高脂血症等疾病的三环氨基醇衍生物的制备方法，该化合物由以下式子表示（1）： 其中R1代表较低的烷基或苄基；*1代表一个不对称碳原子；R2代表氢原子、卤素原子或羟基；A代表以下其中一种基团： 其中X代表NH、O或S；R5代表氢原子、羟基、氨基或乙酰氨基；*2代表一个不对称碳原子，当R5不是氢原子时。本发明的方法通过叠氮衍生物进行，是方便、实用、成本低廉的制备方法，包括少量步骤且具有良好的工业工作效率。
• DNA Strand Scissions by Hydroxamic Acids-Copper(II) Ion under Aerobic Conditions
  作者：Shigeki Hashimoto、Rinichi Yamashita、Yushin Nakamura

  DOI：10.1246/cl.1992.1639

  日期：1992.9

  Carbazolyloxyacetohydroxamic acid (1), 9,9′-decamethylene-bis-carbazolyloxyacetohydroxamic acid (2), benzohydroxamic acid (3) and acetohydroxamic acid (4) without reducing agent under aerobic conditions induced Col E1 DNA strand scissions with increasing of the activities in the order of 4 > 3 > 2 > 1. Inhibition experiments indicated that hydrogen peroxide and superoxide participated in the reactions

  咔唑基氧基乙酰异羟肟酸 (1)、9,9'-十亚甲基-双-咔唑基氧基乙酰异羟肟酸 (2)、苯异羟肟酸 (3) 和乙酰异羟肟酸 (4) 在有氧条件下不使用还原剂诱导 Col E1 DNA 链断裂，其中活性增加4 > 3 > 2 > 1 的顺序。抑制实验表明过氧化氢和超氧化物参与了反应，但羟基自由基或单线态氧没有参与。
• N-Substituted carbazolyloxyacetic acids modulate Alzheimer associated γ-secretase
  作者：Rajeshwar Narlawar、Blanca I. Pérez Revuelta、Karlheinz Baumann、Robert Schubenel、Christian Haass、Harald Steiner、Boris Schmidt

  DOI：10.1016/j.bmcl.2006.09.061

  日期：2007.1

  N-Sulfonylated and N-alkylated carbazolyloxyacetic acids were investigated for the inhibition and modulation of the Alzheimer's disease associated gamma-secretase. The introduction of a lipophilic substituent, which may vary from arylsulfone to alkyl, turned 2-carbazolyloxyacetic acids into potent gamma-secretase modulators. This resulted in the selective reduction of A beta(42) and an increase of the less aggregatory A beta(38) fragment by several compounds (e.g., 7d and 8c). Introduction of an electron donating group at position 6 and 8 of N-substituted carbazolyloxyacetic acids either decreased the activity or inversed modulation. The most active compounds displayed activity on amyloid precursor protein (APP) overexpressing cell lines in the low micromolar range and little or no effect on the gamma-secretase cleavage at the F-site. (c) 2006 Elsevier Ltd. All rights reserved.
• Novel Carvedilol Analogues That Suppress Store-Overload-Induced Ca²⁺ Release
  作者：Chris D. Smith、Aixia Wang、Kannan Vembaiyan、Jingqun Zhang、Cuihong Xie、Qiang Zhou、Guogen Wu、S. R. Wayne Chen、Thomas G. Back

  DOI：10.1021/jm401090a

  日期：2013.11.14

  Carvedilol is a uniquely effective drug for the treatment of cardiac arrhythmias in patients with heart failure. This activity is in part because of its ability to inhibit store-overload-induced calcium release (SOICR) through the RyR2 channel. We describe the synthesis, characterization, and bioassay of ca. 100 compounds based on the carvedilol motif to identify features that correlate with and optimize SOICR inhibition. A single-cell bioassay was employed on the basis of the RyR2-R4496C mutant HEK-293 cell line in which calcium release from the endoplasmic reticulum through the defective channel was measured. IC50 values for SOICR inhibition were thus obtained. The compounds investigated contained modifications to the three principal subunits of carvedilol, including the carbazole and catechol moieties, as well as the linker chain containing the beta-amino alcohol functionality. The SAR results indicate that significant alterations are tolerated in each of the three subunits.